

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1600RXA

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 FEB 25 CA/CAPLUS - Russian Agency for Patents and Trademarks  
(ROSPATENT) added to list of core patent offices covered  
NEWS 4 FEB 28 PATDPAFULL - New display fields provide for legal status  
data from INPADOC  
NEWS 5 FEB 28 BABS - Current-awareness alerts (SDIs) available  
NEWS 6 FEB 28 MEDLINE/LMEDLINE reloaded  
NEWS 7 MAR 02 GBFULL: New full-text patent database on STN  
NEWS 8 MAR 03 REGISTRY/ZREGISTRY - Sequence annotations enhanced  
NEWS 9 MAR 03 MEDLINE file segment of TOXCENTER reloaded  
NEWS 10 MAR 22 KOREAPAT now updated monthly; patent information enhanced  
NEWS 11 MAR 22 Original IDE display format returns to REGISTRY/ZREGISTRY  
NEWS 12 MAR 22 PATDPASPC - New patent database available  
NEWS 13 MAR 22 REGISTRY/ZREGISTRY enhanced with experimental property tags  
NEWS 14 APR 04 EPFULL enhanced with additional patent information and new  
fields  
NEWS 15 APR 04 EMBASE - Database reloaded and enhanced  
  
NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 13:45:31 ON 08 APR 2005

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 13:45:38 ON 08 APR 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 7 APR 2005 HIGHEST RN 848122-48-5  
DICTIONARY FILE UPDATES: 7 APR 2005 HIGHEST RN 848122-48-5

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.


\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more  
information enter HELP PROP at an arrow prompt in the file or refer  
to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10661947.str



chain nodes :

6 14 15 16 17 18 19

ring nodes :

1 2 3 4 5 7 8 9 10 11 12

chain bonds :

2-14 3-6 5-17 6-7 17-18 18-19

ring bonds :

1-2 1-5 2-3 3-4 4-5 7-8 7-12 8-9 9-10 10-11 11-12

exact/norm bonds :


1-2 1-5 3-6 4-5 5-17 6-7 18-19

exact bonds :  
2-3 2-14 3-4 17-18  
normalized bonds :  
7-8 7-12 8-9 9-10 10-11 11-12  
isolated ring systems :  
containing 1 :

Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS  
20:CLASS 21:CLASS

L1 STRUCTURE UPLOADED

=> d  
L1 HAS NO ANSWERS  
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1  
SAMPLE SEARCH INITIATED 13:45:59 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 380 TO ITERATE

100.0% PROCESSED 380 ITERATIONS  
SEARCH TIME: 00.00.01

8 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 6431 TO 8769  
PROJECTED ANSWERS: 8 TO 329

L2 8 SEA SSS SAM L1

=> s l1 full  
FULL SEARCH INITIATED 13:46:02 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 7767 TO ITERATE

100.0% PROCESSED 7767 ITERATIONS  
SEARCH TIME: 00.00.01

203 ANSWERS

L3 203 SEA SSS FUL L1

=> s 13 and caplus/lc  
45431149 CAPLUS/LC


L4 190 L3 AND CAPLUS/LC

=> s 13 not 14

L5 13 L3 NOT L4


=> d 15 1-13

L5 ANSWER 1 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 380425-94-5 REGISTRY  
 ED Entered STN: 04 Jan 2002  
 CN 1H-Pyrazole-1-ethanol, 4-(2-hydroxyphenoxy)-3,5-dimethyl- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C13 H16 N2 O3  
 SR Chemical Library  
 LC STN Files: CHEMCATS



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L5 ANSWER 2 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 266362-64-5 REGISTRY  
 ED Entered STN: 24 May 2000  
 CN 1H-Pyrazole-1-acetamide, 3,5-dimethyl-N-[3-(methylthio)phenyl]-4-phenoxy- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C20 H21 N3 O2 S  
 SR CAS Client Services  
 LC STN Files: CHEMCATS



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


**BEST AVAILABLE COPY**

L5 ANSWER 3 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 266362-63-4 REGISTRY  
 ED Entered STN: 24 May 2000  
 CN 1H-Pyrazole-1-acetamide, 3,5-dimethyl-4-phenoxy-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C20 H18 F3 N3 O2  
 SR CAS Client Services




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L5 ANSWER 4 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 266362-62-3 REGISTRY  
 ED Entered STN: 24 May 2000  
 CN 1H-Pyrazole-1-acetamide, N-(3-chlorophenyl)-3,5-dimethyl-4-phenoxy- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C19 H18 Cl N3 O2  
 SR CAS Client Services  
 LC STN Files: CHEMCATS




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

LS ANSWER 5 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 266362-61-2 REGISTRY  
 ED Entered STN: 24 May 2000  
 CN 1H-Pyrazole-1-acetanide, 3,5-dimethyl-4-phenoxy-N-phenyl- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C19 H19 N3 O2  
 SR CAS Client Services  
 LC STN Files: CHEMCATS




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

LS ANSWER 6 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 264626-26-8 REGISTRY  
 ED Entered STN: 12 May 2000  
 CN 1H-Pyrazole-1-carboxamide, 4-(4-chlorophenoxy)-3,5-dimethyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C15 H18 Cl N3 O2  
 SR CAS Client Services  
 LC STN Files: CHEMCATS




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

LS ANSWER 7 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 264626-25-7 REGISTRY  
 ED Entered STN: 12 May 2000  
 CN 1H-Pyrazole-1-carboxamide, 4-(4-chlorophenoxy)-3,5-dimethyl-N-phenyl- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C18 H16 Cl N3 O2  
 SR CAS Client Services  
 LC STN Files: CHEMCATS




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

LS ANSWER 8 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 264626-24-6 REGISTRY  
 ED Entered STN: 12 May 2000  
 CN 1H-Pyrazole-1-carboxamide, 3,5-dimethyl-N-(1-methylethyl)-4-phenoxy- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C15 H19 N3 O2  
 SR CAS Client Services




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L5 ANSWER 9 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 264626-23-5 REGISTRY  
 ED Entered STN: 12 May 2000  
 CN 1H-Pyrazole-1-carboxamide, 3,5-dimethyl-4-phenoxy-N-phenyl- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C18 H17 N3 O2  
 SR CAS Client Services  
 LC STN Files: CHEMCATS




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L5 ANSWER 10 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 264616-90-2 REGISTRY  
 ED Entered STN: 12 May 2000  
 CN 1H-Pyrazole, 1-benzoyl-3,5-dimethyl-4-phenoxy- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C18 H16 N2 O2  
 SR CAS Client Services  
 LC STN Files: CHEMCATS




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L5 ANSWER 11 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 264616-89-9 REGISTRY  
 ED Entered STN: 12 May 2000  
 CN 1H-Pyrazole, 4-(4-chlorophenoxy)-1-(cyclopropylcarbonyl)-3,5-dimethyl- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C15 H15 Cl N2 O2  
 SR CAS Client Services  
 LC STN Files: CHEMCATS




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L5 ANSWER 12 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 264616-88-8 REGISTRY  
 ED Entered STN: 12 May 2000  
 CN 1H-Pyrazole, 1-benzoyl-4-(4-chlorophenoxy)-3,5-dimethyl- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C18 H15 Cl N2 O2  
 SR CAS Client Services  
 LC STN Files: CHEMCATS



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

LS ANSWER 13 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 263767-20-0 REGISTRY  
ED Entered STN: 04 May 2000  
CN 1H-Pyrazole, 1-(4-chlorobenzoyl)-4-(4-chlorophenoxy)-3,5-dimethyl- (9CI)  
(CA INDEX NAME)  
PS 3D CONCORD  
MF C18 H14 Cl2 N2 O2  
SR CAS Client Services



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*



=> fil caplus  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
190.71	190.92

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 13:47:22 ON 08 APR 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Apr 2005 VOL 142 ISS 16  
FILE LAST UPDATED: 7 Apr 2005 (20050407/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 13:45:31 ON 08 APR 2005)

FILE 'REGISTRY' ENTERED AT 13:45:38 ON 08 APR 2005

L1	STRUCTURE UPLOADED
L2	8 S L1
L3	203 S L1 FULL
L4	190 S L3 AND CAPLUS/LC
L5	13 S L3 NOT L4

FILE 'CAPLUS' ENTERED AT 13:47:22 ON 08 APR 2005



=> s l4

L6 18 L4

=> d ibib abs hitstr 16 1-18


L6 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2004:308433 CAPLUS  
 DOCUMENT NUMBER: 140:321352  
 TITLE: Preparation of pyrazole derivatives as HIV reverse transcriptase inhibitors  
 INVENTOR(S): Price, David Anthony; Selby, Matthew Duncan; Stupples, Paul Anthony  
 PATENT ASSIGNER(S): Pfizer Limited, UK; Pfizer Inc.  
 SOURCE: PCT Int. Appl., 43 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004031178	A1	20040415	WO 2003-184205	20030924
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TH, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004133002	A1	20040708	US 2003-669819	20030923
PRIORITY APPLN. INFO.:			GB 2002-23232	A 20021007
			US 2002-432859P	P 20021211
OTHER SOURCE(S):		MARPAT 140:321352		
GI				




AB The title compds. [I; WKY = (un)substituted 5-6 membered partially saturated or aromatic ring containing 0-3 N atoms wherein X = CH or N and Y = CH or, when X = CH, may also be N; R1 = alkylene; R2 = H, alkyl, cycloalkyl, etc.; R3 = H, alkyl, cycloalkyl, Ph, etc.; R4 = (un)substituted Ph, naphthyl,

L6 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 678992-37-5 CAPLUS  
 CN 1H-Pyrazole, 1-acetyl-5-(bromomethyl)-4-(3,5-dicyanophenoxy)-3-methyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 pyridyl; n = 0-2] which bind to the enzyme reverse transcriptase and are modulators, esp. inhibitors thereof, and as such are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated, were prepd. Disorders of interest include those caused by Human Immunodeficiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS). Thus, reacting 3-(5-aminoethyl-3-methyl-1H-pyrazol-4-yl)-5-chlorobenzonitrile (prepn. given) with Me 2-formylbenzoate in the presence of NaH(OAc)3 and AcOH in CH2Cl2 afforded II which showed IC50 of 76 nM against HIV-1 reverse transcriptase. The pharmaceutical compn. comprising the compd. I is claimed.  
 IT 473923-70-8P 473923-73-8P 473924-23-1P  
 678992-37-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 RN (preparation of pyrazole derivs. as HIV reverse transcriptase inhibitors)  
 CN 473923-70-5 CAPLUS  
 CN 1H-Pyrazole, 1-acetyl-4-(3-chloro-5-cyanophenoxy)-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 473923-73-8 CAPLUS  
 CN 1H-Pyrazole, 1-acetyl-3-(bromomethyl)-4-(3-chloro-5-cyanophenoxy)-5-methyl- (9CI) (CA INDEX NAME)



RN 473924-23-1 CAPLUS  
 CN 1H-Pyrazole, 1-acetyl-4-(3,5-dicyanophenoxy)-3,5-dimethyl- (9CI) (CA INDEX NAME)

L6 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2004:292024 CAPLUS  
 DOCUMENT NUMBER: 140:303665  
 TITLE: Preparation of pyrazole amides for treating HIV infections  
 INVENTOR(S): Jones, Lyn Howard; Mowbray, Charles Eric; Price, David  
 PATENT ASSIGNER(S): Pfizer Limited, UK; Pfizer Inc.  
 SOURCE: PCT Int. Appl., 55 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004029051	A1	20040408	WO 2003-184071	20030915
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TH, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005004129	A1	20050106	US 2003-669794	20030923
PRIORITY APPLN. INFO.:			GB 2002-22375	A 20020926
			GB 2002-23357	A 20021008
			US 2002-433220P	P 20021213
OTHER SOURCE(S):		MARPAT 140:303665		
GI				




AB The title compds. [I; WKY = (un)substituted 5-6 membered partially saturated or aromatic ring containing 0-3 N atoms wherein X = CH or N and Y = CH or, when X = CH, may also be N; R1 = a bond, alkylene, R2 = H, alkyl, cycloalkyl, etc.; R3 = H, alkyl, cycloalkyl, etc.; R4 = (un)substituted Ph, naphthyl, pyridyl; n = 0-2] which bind to the enzyme reverse transcriptase and are

L6 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
modulators, esp. inhibitors thereof, were prepd. and formulated. Thus, reacting [4-(3,5-dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]acetic acid (prepn. given) with 5,6,7,8-tetrahydro-[1,6]naphthyridine afforded II. The compds. I were tested for inhibition of HIV-1 reverse transcriptase enzyme (data were given for representative compds. I). The compds. I are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodeficiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).

IT 473923-49-8P 473923-52-3P 473923-70-5P  
473923-73-8P 676994-56-2P 676994-57-3P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


RN 473923-49-8 CAPLUS  
(preparation of pyrazole amides for treating HIV infections)

CN 1H-Pyrazole, 1-acetyl-4-(3,5-dichlorophenoxy)-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 473923-52-3 CAPLUS

CN 1H-Pyrazole, 1-acetyl-3-(bromomethyl)-4-(3,5-dichlorophenoxy)-5-methyl- (9CI) (CA INDEX NAME)



RN 473923-70-5 CAPLUS


CN 1H-Pyrazole, 1-acetyl-4-(3-chloro-5-cyanophenoxy)-3,5-dimethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT:


1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 473923-73-8 CAPLUS

CN 1H-Pyrazole, 1-acetyl-3-(bromomethyl)-4-(3-chloro-5-cyanophenoxy)-5-methyl- (9CI) (CA INDEX NAME)



RN 676994-56-2 CAPLUS

CN 1H-Pyrazole, 4-(3,5-dicyanophenoxy)-1-(2,2-dimethyl-1-oxopropyl)-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 676994-57-3 CAPLUS


CN 1H-Pyrazole, 5-(bromomethyl)-4-(3,5-dicyanophenoxy)-1-(2,2-dimethyl-1-oxopropyl)-3-methyl- (9CI) (CA INDEX NAME)

L6 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:287840 CAPLUS  
DOCUMENT NUMBER: 140:303663  
TITLE: Preparation of pyrazole derivatives as reverse transcriptase inhibitors  
INVENTOR(S): Barba, Oscar; Jones, Lyn Howard  
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.  
SOURCE: PCT Int. Appl., 41 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004029042	A1	20040408	WO 2003-1B4158	20030915
US 2004110816	A1	20040610	US 2003-669812	20030923
PRIORITY APPLN. INFO.:			GB 2002-22374	A 20020926
			GB 2002-23356	A 20021008
			US 2002-433402P	P 20021213

OTHER SOURCE(S): HARPAT 140:303663  
GI




AB The title compds. [I; R1 = (un)substituted 5-6 membered heteroaryl


containing  
(1) 1-4 N atoms or (2) 1-2 N atoms and 1 O atom or 1 S atom or (3) 1 or 2 O or S atoms; R2 = H, alkyl, cycloalkyl, etc.; R3 = H, alkyl, cycloalkyl, etc.; R4 = (un)substituted Ph, naphthyl, pyridyl which bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof, were

prepared and formulated. Thus, reacting 5-(3-ethyl-1-methyl-5-oxo-4,5-dihydro-1H-pyrazol-4-yl)oxyisophthalonitrile (preparation given) with 2-chloropyridine afforded I [R1 = 2-pyridyl; R2 = Me; R3 = Et; R4 = 3,5-dicyanophenyl] which showed IC50 of 5400 nM against HIV-1 reverse transcriptase. The compds. I are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human

L6 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)  
Immunodeficiency Virus (HIV) and genetically related retroviruses, such as  
Acquired Immune Deficiency Syndrome (AIDS).  
IT 676995-20-3P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)  
(preparation of pyrazole derivs. as reverse transcriptase inhibitors)  
RN 676995-20-3 CAPLUS  
CN 1,3-Benzenediacetonitrile, 5-[[3-ethyl-1-(2-hydroxyethyl)-5-(2-  
pyridinyl)oxy]-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



IT 676995-24-7P 676995-26-9P 676995-27-0P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of pyrazole derivs. as reverse transcriptase inhibitors)  
RN 676995-24-7 CAPLUS  
CN 1,3-Benzenediacetonitrile, 5-[[3-ethyl-4,5-dihydro-5-oxo-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 676995-26-9 CAPLUS  
CN 1,3-Benzenediacetonitrile, 5-[[1-(2-[[1-(1,1-dimethylethyl)dimethylsilyl]oxy]  
[ethyl]-3-ethyl-4,5-dihydro-5-oxo-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX  
NAME)

L6 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2005 ACS ON STN  
ACCESSION NUMBER: 2004:253142 CAPLUS  
DOCUMENT NUMBER: 140:287377  
TITLE: Preparation of pyrazoloxisophthalonitrile as  
reverse transcriptase inhibitor in the treatment of  
AIDS  
INVENTOR(S): Nowbary, Charles Eric; Price, David Anthony; Selby,  
Matthew Duncan; Stupples, Paul Anthony  
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.  
SOURCE: PCT Int. Appl., 32 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004024147	A1	20040325	WO 2003-1B3946	20030908
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GI, GR, GU, HK, HN, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004132793	A1	20040708	US 2003-661947	20030912
PRIORITY APPL. INFO.: GB 2002-21477 A 20020916 GB 2002-23354 A 20021008 US 2002-43397P P 20021213				

GI




AB This invention relates to 5-[[3-cyclopropyl-1-(2-hydroxyethyl)-5-methyl-1H-pyrazol-4-yl]oxy]isophthalonitrile (shown as I) and pharmaceutically acceptable salt, solvate or derivs. thereof, to their use in medicine, to compns. containing them, to processes for their preparation and to intermediates used in such processes. I binds to the enzyme reverse transcriptase (IC50 = 295 nM) and is an inhibitor thereof. I had t1/2 >120 min in human liver microsomes and Supermix; it had an unbound hepatocyte clearance <9 nL/min/kg in human hepatocytes. Reverse transcriptase is implicated in the infectious life cycle of Human Immunodeficiency Virus (HIV). Compds. which interfere with the function of this enzyme showed utility in the treatment of conditions caused by HIV and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS) (no

L6 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)




RN 676995-27-0 CAPLUS  
CN 1,3-Benzenediacetonitrile, 5-[[1-(2-[[1-(1,1-dimethylethyl)dimethylsilyl]oxy]  
[ethyl]-3-ethyl-5-(2-pyridinyl)oxy]-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX  
NAME)




REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)  
data). Two examples of the prep. of I are given: cyclocondensation of  
2-hydroxyethylhydrazine with 5-[[1-(cyclopropylcarbonyl)-2-oxopropoxy]isophthalonitrile (and sepn. of regioisomers) and deprotection  
of 5-[[3-cyclopropyl-5-methyl-1-(2-(tetrahydro-2H-pyran-2-yloxy)ethyl)-1H-pyrazol-4-yl]oxy]isophthalonitrile; prep. of the reactants is described.  
IT 675198-29-5P, 5-[[3-cyclopropyl-1-(2-hydroxyethyl)-5-methyl-1H-pyrazol-4-yl]oxy]isophthalonitrile  
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(drug candidate; preparation of pyrazoloxisophthalonitrile as reverse transcriptase inhibitor in treatment of AIDS)  
RN 675198-29-5 CAPLUS  
CN 1,3-Benzenediacetonitrile, 5-[[3-cyclopropyl-1-(2-hydroxyethyl)-5-methyl-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)




IT 675198-33-1P, 5-[[3-cyclopropyl-5-methyl-1-(2-(tetrahydro-2H-pyran-2-yloxy)ethyl)-1H-pyrazol-4-yl]oxy]isophthalonitrile  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of pyrazoloxisophthalonitrile as reverse transcriptase inhibitor in treatment of AIDS)  
RN 675198-33-1 CAPLUS  
CN 1,3-Benzenediacetonitrile, 5-[[3-cyclopropyl-5-methyl-1-(2-(tetrahydro-2H-pyran-2-yloxy)ethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)




IT 675198-30-8P, 5-[[5-Cyclopropyl-1-(2-hydroxyethyl)-3-methyl-1H-pyrazol-4-yl]oxy]isophthalonitrile 675198-34-2P, 5-[[5-Cyclopropyl-3-methyl-1-(2-(tetrahydro-2H-pyran-2-yloxy)ethyl)-1H-pyrazol-4-yl]oxy]isophthalonitrile

L6 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of pyrazoloxysophthalonitrile as reverse transcriptase  
inhibitor in treatment of AIDS)  
RN 675198-30-8 CAPLUS  
CN 1,3-Benzenedicarbonitrile, 5-[[5-cyclopropyl-1-(2-hydroxyethyl)-3-methyl-  
1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 675198-34-2 CAPLUS  
CN 1,3-Benzenedicarbonitrile, 5-[[5-cyclopropyl-3-methyl-1-(2-[[tetrahydro-2H-  
pyran-2-yl]oxy]ethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)  
ACCESSION NUMBER: 2002:832763 CAPLUS  
DOCUMENT NUMBER: 137:337884  
TITLE: Preparation of aryloxy pyrazole derivatives as reverse  
transcriptase inhibitors for treating HIV  
INVENTOR(S): Jones, Lyn Howard; Mowbray, Charles Eric; Price, Davis  
Anthony; Selby, Matthew Duncan; Stupples, Paul Anthony  
PATENT ASSIGNER(S): Pfizer Limited, UK; Pfizer Inc.  
SOURCE: PCT Int. Appl., 306 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085960	A1	20021031	WO 2002-1B1234	20020404
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GR, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2443449	AA	20021031	CA 2002-2443449	20020404
EP 1377556	A1	20040107	EP 2002-708600	20020404
R: AT, BR, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300497	A	20040216	EE 2003-497	20020404
BR 2002008811	A	20040309	BR 2002-8811	20020404
JP 2004531535	T2	20041014	JP 2002-583387	20020404
US 2003100554	A1	20030529	US 2002-118512	20020405
ZA 2003007095	A	20040910	ZA 2003-7095	20030910
NO 2003004523	A	20031209	NO 2003-4523	20031009
PRIORITY APPL. INFO.:				
GB 2001-8999	A	20010410	GB 2001-27426	A 20011115
US 2001-289570P	P	20010508	US 2002-346727P	P 20020107
WO 2002-1B1234	V	20020404		

OTHER SOURCE(S): MARPAT 137:337884



AB This invention relates to pyrazole derivs. (shown as 1; e.g. 2-Amino-6-[[4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]methyl]-

L6 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2005 ACS ON STN  
ACCESSION NUMBER: 2003:174492 CAPLUS  
DOCUMENT NUMBER: 138:198678  
TITLE: Small-molecule modulators of hepatocyte growth  
factor/scatter factor activities as drugs  
INVENTOR(S): Pillariseti, Sivaram; Goldberg, Itzhak D.  
PATENT ASSIGNER(S): USA  
SOURCE: U.S. Pat. Appl. Publ., 37 pp.  
CODEN: USXOCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003045559	A1	20030306	US 2001-896832	20010629
US 6589997	B2	20030708		
US 2003022924	A1	20030130	US 2001-26672	20011219
US 6610726	B2	20030826		
US 2003216459	A1	20031120	US 2003-456326	20030606
US 6855728	B2	20050215		

PRIORITY APPL. INFO.: MARPAT 138:198678

AB The invention is directed to small organic mols. having the ability to mimic or agonize hepatocyte growth factor/scatter factor (HGF/SF) activity, or inhibit or antagonize HGF/SF activity, the former useful for promoting, for example, vascularization of tissues or organs for promoting wound or tissue healing, or augmenting or restoring blood flow to ischemic tissues such as the heart following myocardial infarction. Inhibition of cellular growth or proliferation is beneficial in the treatment, for example, of inflammatory diseases such as inflammatory joint and skin diseases, and dysproliferative diseases such as cancer. Pharmaceutical compns. containing the modulators are also claimed.

IT 264616-91-3  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(small-mol. modulators of hepatocyte growth factor/scatter factor activities as drugs)


RN 264616-91-3 CAPLUS  
CN 1H-Pyrazole, 1-(4-chlorobenzoyl)-3,5-dimethyl-4-phenoxy- (9CI) (CA INDEX NAME)




L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)  
4(3H)-pyrimidinone) or pharmaceutically acceptable salts, solvates or deriv. thereof, wherein R1 to R4 are defined below, and to processes for the prepn. thereof, intermediates used in their prepn. of, compns. contg. then and the uses of such derivs. The compds. of the present invention bind to the enzyme reverse transcriptase and are modulators, esp. inhibitors thereof. As such the compds. of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodeficiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS). In tests of inhibition of HIV-1 reverse transcriptase enzyme, the claimed compds. 2-amino-6-[[4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]methyl]-4(3H)-pyrimidinone, 3,5-dimethyl-4-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile and 1-(3-azetidinyl)-4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazole had IC50 values of 39,000, 3,200 and 248 nM, resp. In 1: R1 is H, Cl-C6 alkyl, C3-C7 cycloalkyl, Ph, benzyl, halo, -CN, -OR7, -CO2R10, -CONSR10, R8 or R9. R2 is H, Cl-C6 alkyl, C3-C6 alkenyl, C3-C6 alkynyl, C3-C7 cycloalkyl, C3-C7 cycloalkenyl, Ph, benzyl, R8 or R9; or R1 and R2, when taken together, represent unbranched C3-C4 alkylene. R3 is H, Cl-C6 alkyl, C3-C7 cycloalkyl, Ph, benzyl, halo, -CN, -OR7, -CO2R5, -CONSR5, R8 or R9; R4 is Ph, naphthyl or pyridyl. Definitions of R5 and R7-R10 and addnl. specifications are given in the claims. Included are 283 claimed compd. prepn. and 115 intermediate prepn.

IT 473919-45-8P, 2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol 473919-54-8P, Methyl 4-[(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]acetate 473919-56-1P, 2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]acetohydrazide 473919-83-4P, 2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol 473920-32-0P, Ethyl 4-[(3-cyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]acetate 473920-89-7P, 5-[[1-(2-Hydroxyethyl)-3-isopropyl-5-methyl-1H-pyrazol-4-yl]oxy]isophthalonitrile 473921-04-9P, 3-Chloro-5-[[1-(2-hydroxyethyl)-3,5-diethyl-1H-pyrazol-4-yl]oxy]benzonitrile 473921-10-7P, 3-Fluoro-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile 473921-11-8P, 3-Methyl-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile 473921-12-9P, 3-Cyano-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile 473921-50-5P, 5-[[3-tert-Butyl-1-(2-hydroxyethyl)-5-methyl-1H-pyrazol-4-yl]oxy]isophthalonitrile 473921-56-1P, 3-[[1H-Pyrazol-1-yl]-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile 473921-60-7P, 3-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-fluorobenzamide 473921-63-0P, 5-[[5-Ethyl-1-(2-hydroxyethyl)-3-isopropyl-5-methyl-1H-pyrazol-4-yl]oxy]isophthalonitrile 473921-73-2P, 5-[[3,5-Diethyl-1-((methoxycarbonyl)methyl)-1H-pyrazol-4-yl]oxy]-1,3-benzenedicarbonitrile 473921-83-6P, 3-[[3-Cyclopropyl-1-(2-hydroxyethyl)-5-methyl-1H-pyrazol-4-yl]oxy]-5-methylbenzonitrile 473921-96-9P, 3-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-methoxybenzonitrile 473922-65-5P, 3-[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(methylsulfonyl)benzonitrile 473922-87-1P, 5-[[3,5-Diethyl-1-(2-[[2-methoxyethoxy]methoxy]ethyl)-1H-pyrazol-4-yl]oxy]isophthalonitrile 473923-08-9P, Di(tert-butyl) 2-[4-(3,5-dicyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethyl phosphate  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(drug candidate) preparation of aryloxy pyrazole derivs. as reverse transcriptase inhibitors for treating HIV)

L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 RN 473919-45-8 CAPLUS  
 CN 1H-Pyrazole-1-ethanol, 4-(3,5-dichlorophenoxy)-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 473919-54-9 CAPLUS  
 CN 1H-Pyrazole-1-acetic acid, 4-(3,5-dichlorophenoxy)-3,5-diethyl-, methyl ester (9CI) (CA INDEX NAME)




RN 473919-56-1 CAPLUS  
 CN 1H-Pyrazole-1-acetic acid, 4-(3,5-dichlorophenoxy)-3,5-diethyl-, hydrazide (9CI) (CA INDEX NAME)


L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 473919-83-4 CAPLUS  
 CN 1H-Pyrazole-1-ethanol, 4-(3,5-difluorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)




RN 473920-32-0 CAPLUS  
 CN 1H-Pyrazole-1-acetic acid, 4-(3-cyanophenoxy)-3,5-diethyl-, ethyl ester (9CI) (CA INDEX NAME)




L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 RN 473920-89-7 CAPLUS  
 CN 1,3-Benzenedicarbonitrile, 5-[[1-(2-hydroxyethyl)-5-methyl-3-(1-methylethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 473921-04-9 CAPLUS  
 CN Benzonitrile, 3-chloro-5-[[1-(2-hydroxyethyl)-3,5-dimethyl-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 473921-10-7 CAPLUS  
 CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-fluoro- (9CI) (CA INDEX NAME)




L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 RN 473921-11-8 CAPLUS  
 CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-methyl- (9CI) (CA INDEX NAME)



RN 473921-12-9 CAPLUS  
 CN 1,3-Benzenedicarbonitrile, 5-[[3-(1,1-dimethylethyl)-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 473921-50-5 CAPLUS  
 CN 1,3-Benzenedicarbonitrile, 5-[[3-(1,1-dimethylethyl)-1-(2-hydroxyethyl)-5-methyl-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 473921-56-1 CAPLUS

CN Benzonitrile, 3-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)




RN 473921-60-7 CAPLUS

CN Benamide, 3-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-fluoro- (9CI) (CA INDEX NAME)




RN 473921-63-0 CAPLUS

CN 1,3-Benzenedicarbonitrile, 5-[[[5-ethyl-1-(2-hydroxyethyl)-3-(1-methylethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 473921-73-2 CAPLUS

CN 1H-Pyrazole-1-acetic acid, 4-(3,5-dicyanophenoxy)-3,5-diethyl-, methyl ester (9CI) (CA INDEX NAME)




L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CN Benzonitrile, 3-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(methylthio)- (9CI) (CA INDEX NAME)




RN 473922-87-1 CAPLUS

CN 1,3-Benzenedicarbonitrile, 5-[[[3,5-diethyl-1-(2-{(2-methoxyethoxy)methoxy}ethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 473923-08-9 CAPLUS

CN Phosphoric acid, 2-[4-(3,5-dicyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 473921-85-6 CAPLUS

CN Benzonitrile, 3-[[[3-cyclopropyl-1-(2-hydroxyethyl)-5-methyl-1H-pyrazol-4-yl]oxy]-5-methyl- (9CI) (CA INDEX NAME)




RN 473921-96-9 CAPLUS

CN Benzonitrile, 3-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-methoxy- (9CI) (CA INDEX NAME)



RN 473922-65-5 CAPLUS




L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


IT 473919-46-9P, 2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol 473919-55-0P, 2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]acetamide 473919-62-9P, 3-[[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile 473919-65-2P, 2-[4-(2,6-Dimethyl-4-cyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol 473919-66-3P, 2-[4-(2-Chloro-4-cyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol 473919-67-4P, 2-[4-(4-Fluoro-3-cyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol 473919-68-5P, 2-[4-(4-Chlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol 473919-69-6P, 2-[4-(3-Chlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol 473919-70-9P, 2-[4-(2-Chlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol 473919-71-0P, 2-[4-(2,6-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol 473919-72-1P, 2-[4-(2,3-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol 473919-73-2P, 2-[4-(2,4-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol 473919-74-3P, 2-[3,5-Diethyl-4-(2-fluorophenoxy)-1H-pyrazol-1-yl]ethanol 473919-75-4P, 2-[3,5-Diethyl-4-(3-fluorophenoxy)-1H-pyrazol-1-yl]ethanol 473919-76-5P, 2-[4-(3,5-Dimethylphenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol 473919-77-6P, 2-[4-(3-Methyl-4-fluorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol 473919-78-7P, 2-[4-(2,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol 473919-79-8P, 2-[4-(2,3-Difluorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol 473919-80-1P, 2-[4-(3,4-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol 473919-81-2P, 2-[4-(2,6-Difluorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol 473919-82-3P, 2-[4-(2,5-Difluorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol 473919-84-5P, 4-(3,5-Dichlorophenoxy)-3,5-diethyl-1-(2-methoxyethyl)-1H-pyrazole 473919-86-7P, 4-(3,5-Dichlorophenoxy)-3,5-diethyl-1-(methoxymethyl)-1H-pyrazole 473920-14-6P, 1-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]-2-propanol 473920-16-0P, 2-[2-(4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl)ethoxy]ethanamine 473920-21-7P, 2-[4-(3,5-Dichlorophenoxy)-3-ethyl-5-methoxy-1H-pyrazol-1-yl]ethanol 473920-29-5P, 2-[4-(3-Cyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]acetamide 473920-87-5P, 2-[4-(3,5-Dichlorophenoxy)-3-methyl-5-[[[3-pyridinyl]methyl]amino]methyl]-1H-pyrazol-1-yl]ethanol 473921-05-0P, 3-Chloro-5-[[[5-[[[4-cyanobenzyl]amino]methyl]-1-(2-hydroxyethyl)-3-methyl-1H-pyrazol-4-yl]oxy]benzonitrile 473921-13-0P, 3-Chloro-5-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile 473921-39-0P, 3-[[[3,5-Diethyl-1-(2-methoxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile 473921-48-1P, 3-[[[5-(Aminomethyl)-1-(2-hydroxyethyl)-3-methyl-1H-pyrazol-4-yl]oxy]-5-chlorobenzonitrile 473921-52-7P, 3-[[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-[[[1H-1,2,4-triazol-1-yl]benzonitrile 473921-53-8P, 3-(1,4-Dihydro-4-oxo-1-pyridyl)-5-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile 473921-58-4P, 3-[[[1H-1,2,3-Triazol-1-yl]-5-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile 473921-55-0P, 3-(2H-1,2,3-Triazol-2-yl)-5-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile 473921-57-2P, 3-(1,2-Dihydro-2-oxo-1-pyridyl)-5-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile 473921-58-3P, 3-(2,3-Dihydro-3-oxo-1,2-diazin-2-yl)-5-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile 473921-59-4P, 3-[[[2,5-Dihydro-2,3-dimethyl-5-oxo-1H-pyrazol-1-yl]-5-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile 473921-61-8P, 5-[[[3-Cyclopropyl-5-ethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]isophthalonitrile 473921-62-9P, 5-[[[5-Cyclopropyl-3-ethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]isophthalonitrile

L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 473921-64-1P, 5-[[[3-Ethyl-1-(2-hydroxyethyl)-5-isopropyl-1H-pyrazol-4-yl]oxy]isophthalonitrile 473921-65-2P, 2-[4-(3,5-Dicyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethyl carbamate 473921-69-6P, 5-[[[3,5-Diethyl-1-(3-hydroxypropyl)-1H-pyrazol-4-yl]oxy]isophthalonitrile 473921-71-0P, 5-[[[3,5-Diethyl-1-(2-methoxyethyl)-1H-pyrazol-4-yl]oxy]-1,3-benzodiazol-4-yl]benzamide 473921-74-3P, 2-[4-(3,5-Dicyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]acetamide 473921-75-4P, 5-[[[3,5-Diethyl-1-(hydroxymethyl)-1H-pyrazol-4-yl]oxy]isophthalonitrile 473921-83-4P, 5-[[[3,5-Dicyclopropyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]isophthalonitrile 473921-86-7P, 3-[[[5-Cyclopropyl-1-(2-hydroxyethyl)-3-methyl-1H-pyrazol-4-yl]oxy]-5-methylbenzonitrile 473921-91-4P, 3-[[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-4-methoxybenzonitrile 473921-92-5P, 473921-93-5P, 473921-94-7P, 2-[4-(3,5-Bis(1H-pyrazol-1-yl)phenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol 473921-95-8P, 2-[3,5-Diethyl-4-(3-fluoro-5-(1H-pyrazol-1-yl)phenoxy)-1H-pyrazol-1-yl]ethanol 473922-01-9P, 2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]-N-[(2-pyridinyl)methyl]acetamide 473922-67-7P, 3-[[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(methylsulfinyl)benzonitrile 473922-70-2P, 3-[[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(methylsulfonyl)benzonitrile 473922-73-5P, 3-[[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-[2-(dimethylamino)ethoxy]benzonitrile 473922-74-6P, 3-(2-(Methylamino)ethoxy)-5-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile 473922-77-9P, 3-(Aminocarbonylmethoxy)-5-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile 473922-79-1P, 3-(2-Methoxyethoxy)-5-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile 473922-85-9P, 3-Fluoro-5-[[[1-(2-hydroxyethyl)-5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]oxy]benzonitrile 473922-89-3P, 3-Cyano-5-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzamide 473922-93-9P, 5-[[[5-Ethyl-3-(1-hydroxyethyl)-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]isophthalonitrile 473922-94-0P, 3-[[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(5-trifluoromethyl-1,2,4-oxadiazol-3-yl)benzonitrile 473922-96-2P, 3-(5-Methyl-1,2,4-oxadiazol-3-yl)-5-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile 473922-98-4P, 3-(5-Ethyl-1,2,4-oxadiazol-3-yl)-5-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile 473922-99-5P, 3-(5-Isopropyl-1,2,4-oxadiazol-3-yl)-5-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile 473923-11-4P, 2-[4-(3,5-Dicyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethyl dihydrogen phosphate 473923-14-7P, 5-[[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]isophthalonitrile monosulfate 473923-17-0P, 5-[[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]isophthalonitrile mono(benzenesulfonate) 473923-20-5P, 5-[[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]isophthalonitrile monotosylate 473923-24-9P, 5-[[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]isophthalonitrile monomesylate 473924-71-9P, 3-[[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(1H-pyrazol-1-yl)benzamide 473924-72-0P, 3-[[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(2-oxo-1(2H)-pyridinyl)benzamide 473924-73-1P, 3-[[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(6-oxo-1(6H)-pyridazinyl)benzamide 473924-74-2P, 3-[[[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(2,3-dimethyl-5-oxo-2,5-dihydro-1H-pyrazol-1-yl)benzamide  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; prepn. of arylalkoxy pyrazole derivs. as reverse

L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 transcriptase inhibitors for treating HIV)  
 RN 473919-46-9 CAPLUS  
 CN 1H-Pyrazole-1-ethanol, 4-(3,5-dichlorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)




RN 473919-55-0 CAPLUS  
 CN 1H-Pyrazole-1-acetamide, 4-(3,5-dichlorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)




RN 473919-62-9 CAPLUS  
 CN Benzonitrile, 3-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)


L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 473919-65-2 CAPLUS  
 CN Benzonitrile, 4-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 473919-66-3 CAPLUS  
 CN Benzonitrile, 3-chloro-4-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 473919-67-4 CAPLUS  
 CN Benzonitrile, 5-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-2- (9CI) (CA INDEX NAME)


L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 fluoro- (9CI) (CA INDEX NAME)



RN 473919-68-5 CAPLUS  
 CN 1H-Pyrazole-1-ethanol, 4-(4-chlorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)




RN 473919-69-6 CAPLUS  
 CN 1H-Pyrazole-1-ethanol, 4-(3-chlorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)







L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 RN 473919-70-9 CAPLUS  
 CN 1H-Pyrazole-1-ethanol, 4-(2-chlorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473919-71-0 CAPLUS  
 CN 1H-Pyrazole-1-ethanol, 4-(2,6-dichlorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)




RN 473919-72-1 CAPLUS  
 CN 1H-Pyrazole-1-ethanol, 4-(2,3-dichlorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)




RN 473919-73-2 CAPLUS  
 CN 1H-Pyrazole-1-ethanol, 4-(2,4-dichlorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)


L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 INDEX NAME)



RN 473919-77-6 CAPLUS  
 CN 1H-Pyrazole-1-ethanol, 3,5-diethyl-4-(4-fluoro-3-methylphenoxy)- (9CI) (CA INDEX NAME)




RN 473919-78-7 CAPLUS  
 CN 1H-Pyrazole-1-ethanol, 4-(2,5-dichlorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)




RN 473919-79-8 CAPLUS


L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 INDEX NAME)



RN 473919-74-3 CAPLUS  
 CN 1H-Pyrazole-1-ethanol, 3,5-diethyl-4-(2-fluorophenoxy)- (9CI) (CA INDEX NAME)




RN 473919-75-4 CAPLUS  
 CN 1H-Pyrazole-1-ethanol, 3,5-diethyl-4-(3-fluorophenoxy)- (9CI) (CA INDEX NAME)




RN 473919-76-5 CAPLUS  
 CN 1H-Pyrazole-1-ethanol, 4-(3,5-dimethylphenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)


L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN 1H-Pyrazole-1-ethanol, 4-(2,3-difluorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473919-80-1 CAPLUS  
 CN 1H-Pyrazole-1-ethanol, 4-(2,3,4-dichlorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)




RN 473919-81-2 CAPLUS  
 CN 1H-Pyrazole-1-ethanol, 4-(2,6-difluorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)




RN 473919-82-3 CAPLUS


L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN 1H-Pyrazole-1-ethanol, 4-(2,5-difluorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)



RN 473919-84-5 CAPLUS  
 CN 1H-Pyrazole, 4-(3,5-dichlorophenoxy)-3,5-diethyl-1-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 473919-86-7 CAPLUS  
 CN 1H-Pyrazole, 4-(3,5-dichlorophenoxy)-3,5-diethyl-1-(methoxymethyl)- (9CI) (CA INDEX NAME)




RN 473920-14-8 CAPLUS

L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 473920-29-5 CAPLUS  
 CN 1H-Pyrazole-1-acetamide, 4-(3-cyanophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)




RN 473920-87-5 CAPLUS  
 CN 1H-Pyrazole-1-ethanol, 4-(3,5-dichlorophenoxy)-3-methyl-5-[(3-pyridinylmethyl)amino]methyl- (9CI) (CA INDEX NAME)




RN 473921-05-0 CAPLUS  
 CN Benzonitrile, 3-chloro-5-[[5-[[[(4-cyanophenyl)methyl]amino]methyl]-1-(2-hydroxyethyl)-3-methyl-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)


L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN 1H-Pyrazole-1-ethanol, 4-(3,5-dichlorophenoxy)-3,5-diethyl-α-methyl- (9CI) (CA INDEX NAME)




RN 473920-16-0 CAPLUS  
 CN Ethanamine, 2-[2-[(4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl)ethoxy]- (9CI) (CA INDEX NAME)




RN 473920-21-7 CAPLUS  
 CN 1H-Pyrazole-1-ethanol, 4-(3,5-dichlorophenoxy)-3-ethyl-5-methoxy- (9CI) (CA INDEX NAME)




L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 473921-13-0 CAPLUS  
 CN Benzonitrile, 3-chloro-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 473921-39-0 CAPLUS  
 CN Benzonitrile, 3-[[3,5-diethyl-1-(2-methoxyethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 473921-48-1 CAPLUS


L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
CN Benzonitrile, 3-[[5-(aminomethyl)-1-(2-hydroxyethyl)-3-methyl-1H-pyrazol-4-ylloxy]-5-chloro- (9CI) (CA INDEX NAME)



RN 473921-52-7 CAPLUS  
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(1H-1,2,4-triazol-1-yl)- (9CI) (CA INDEX NAME)




RN 473921-53-8 CAPLUS  
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(4-oxo-1(4H)-pyridinyl)- (9CI) (CA INDEX NAME)




RN 473921-54-9 CAPLUS  
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(1H-1,2,3-triazol-1-yl)- (9CI) (CA INDEX NAME)


L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 473921-59-4 CAPLUS  
CN Benzonitrile, 3-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(2,5-dihydro-2,3-dimethyl-5-oxo-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)




RN 473921-61-8 CAPLUS  
CN 1,3-Benzenedicarbonitrile, 5-[[3-cyclopropyl-5-ethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 473921-62-9 CAPLUS  
CN 1,3-Benzenedicarbonitrile, 5-[[5-cyclopropyl-3-ethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)


L6 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 473921-55-0 CAPLUS  
CN Benzonitrile, 3-([3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy)-5-(2H-1,2,3-triazol-2-yl)- (9CI) (CA INDEX NAME)




RN 473921-57-2 CAPLUS  
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(2-oxo-1(2H)-pyridinyl)- (9CI) (CA INDEX NAME)




FN 473921-58-3 CAPLUS  
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(6-oxo-1(6H)-pyridazinyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 473921-64-1 CAPLUS  
CN 1,3-Benzenedicarbonitrile, 5-[[3-ethyl-1-(2-hydroxyethyl)-5-(1-methylethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 473921-65-2 CAPLUS  
CN 1,3-Benzenedicarbonitrile, 5-([1-[2-[(aminocarbonyl)oxy]ethyl]-3,5-diethyl-1H-pyrazol-4-yl]oxy)- (9CI) (CA INDEX NAME)




RN 473921-69-6 CAPLUS  
CN 1,3-Benzenedicarbonitrile, 5-[[3,5-diethyl-1-(3-hydroxypropyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 473921-71-0 CAPLUS  
CN 1,3-Benzenedicarbonitrile, 5-[[3,5-diethyl-1-(2-methoxyethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 473921-74-3 CAPLUS  
CN 1H-Pyrazole-1-acetamide, 4-(3,5-dicyanophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)




RN 473921-75-4 CAPLUS  
CN 1,3-Benzenedicarbonitrile, 5-[[3,5-diethyl-1-(hydroxymethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 473921-92-5 CAPLUS  
CN 1H-Pyrazole-1-ethanol, 3,5-diethyl-4-(1-naphthalenyloxy)- (9CI) (CA INDEX NAME)




RN 473921-93-6 CAPLUS  
CN 1H-Pyrazole-1-ethanol, 3,5-diethyl-4-(2-naphthalenyloxy)- (9CI) (CA INDEX NAME)




RN 473921-94-7 CAPLUS  
CN 1H-Pyrazole-1-ethanol, 4-(3,5-di-1H-pyrazol-1-ylphenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)




RN 473921-83-4 CAPLUS  
CN 1,3-Benzenedicarbonitrile, 5-[[3,5-dicyclopropyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 473921-86-7 CAPLUS  
CN Benzonitrile, 3-[[5-cyclopropyl-1-(2-hydroxyethyl)-3-methyl-1H-pyrazol-4-yl]oxy]-5-methyl- (9CI) (CA INDEX NAME)




RN 473921-91-4 CAPLUS  
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-4-methoxy- (9CI) (CA INDEX NAME)




RN 473921-95-8 CAPLUS  
CN 1H-Pyrazole-1-ethanol, 3,5-diethyl-4-[3-fluoro-5-(1H-pyrazol-1-yl)phenoxy]- (9CI) (CA INDEX NAME)




RN 473922-01-9 CAPLUS  
CN 1H-Pyrazole-1-acetamide, 4-(3,5-dichlorophenoxy)-3,5-diethyl-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)





RN 473922-67-7 CAPLUS  
CN Benzonitrile, 3-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(methylsulfinyl)- (9CI) (CA INDEX NAME)




RN 473922-70-2 CAPLUS  
CN Benzonitrile, 3-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 473922-73-5 CAPLUS  
CN Benzonitrile, 3-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(2-(dimethylamino)ethoxy)- (9CI) (CA INDEX NAME)



RN 473922-85-9 CAPLUS  
CN Benzonitrile, 3-fluoro-5-[[[1-(2-hydroxyethyl)-5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 473922-89-3 CAPLUS  
CN Benzonitrile, 3-cyano-5-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 473922-93-9 CAPLUS  
CN 1,3-Benzenedicarbonitrile, 5-[[[5-ethyl-3-(1-hydroxyethyl)-1-(2-


RN 473922-74-6 CAPLUS  
CN Benzonitrile, 3-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(2-(methylamino)ethoxy)- (9CI) (CA INDEX NAME)




RN 473922-77-9 CAPLUS  
CN Acetamide, 2-(3-cyano-5-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]phenyl)- (9CI) (CA INDEX NAME)




RN 473922-79-1 CAPLUS  
CN Benzonitrile, 3-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(2-methoxyethoxy)- (9CI) (CA INDEX NAME)




RN 473922-94-0 CAPLUS  
CN Benzonitrile, 3-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)- (9CI) (CA INDEX NAME)




RN 473922-96-2 CAPLUS  
CN Benzonitrile, 3-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(5-methyl-1,2,4-oxadiazol-3-yl)- (9CI) (CA INDEX NAME)




RN 473922-98-4 CAPLUS  
CN Benzonitrile, 3-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(5-ethyl-1,2,4-oxadiazol-3-yl)- (9CI) (CA INDEX NAME)



RN 473922-99-5 CAPLUS  
 CN Benzonitrile, 3-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-[(1-methylethyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



RN 473923-11-4 CAPLUS  
 CN 1,3-Benzenedicarbonitrile, 5-[[[3,5-diethyl-1-[2-(phosphonoxy)ethyl]-1H-pyrazol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 473923-14-7 CAPLUS  
 CN 1,3-Benzenedicarbonitrile, 5-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-, sulfate (1:1) (salt) (9CI) (CA INDEX NAME)

CH 1


CRN 473921-12-9  
 C17 H18 N4 O2



RN 473923-20-5 CAPLUS  
 CN 1,3-Benzenedicarbonitrile, 5-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-, mono(4-methylbenzenesulfonate) (salt) (9CI) (CA INDEX NAME)


CH 1

CRN 473921-12-9  
 C17 H18 N4 O2



CH 2


CRN 104-15-4  
 C7 H8 O3 S



RN 473923-24-9 CAPLUS  
 CN 1,3-Benzenedicarbonitrile, 5-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-, monomethanesulfonate (salt) (9CI) (CA INDEX NAME)

CH 1

CRN 473921-12-9  
 C17 H18 N4 O2



CH 2


CRN 7664-93-9  
 C17 H18 N4 O2 S



RN 473923-17-0 CAPLUS  
 CN 1,3-Benzenedicarbonitrile, 5-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-, monobenzenesulfonate (salt) (9CI) (CA INDEX NAME)


CH 1

CRN 473921-12-9  
 C17 H18 N4 O2



CH 2

CRN 98-11-3  
 C6 H6 O3 S




CH 2


CRN 75-75-2  
 C H4 O3 S




RN 473924-71-9 CAPLUS  
 CN Benzanide, 3-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)




RN 473924-72-0 CAPLUS  
 CN Benzanide, 3-[[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-5-(2-oxo-1(2H)-pyridinyl)- (9CI) (CA INDEX NAME)



RN 473924-73-1 CAPLUS  
CN Benzamide, 3-[(3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl)oxy]-5-(6-oxo-1(6H)-pyridazinyl)- (9CI) (CA INDEX NAME)




RN 473924-74-2 CAPLUS  
CN Benzamide, 3-[(3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl)oxy]-5-(2,5-dihydro-2,3-dimethyl-5-oxo-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)




IT 473923-41-0P, Ethyl 4-[4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]-3-oxobutanoate 473923-43-2P, 4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl)acetic acid

L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)  
(methylsulfanyl)benzonitrile 473924-43-5P, 3-[(3,5-Diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl)oxy]-5-[2-(dimethylamino)ethoxy]benzonitrile 473924-44-6P, 3-[(3,5-Diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl)oxy]-5-(2-(methylamino)ethoxy)benzonitrile 473924-45-7P, 3-[(3,5-Diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl)oxy]-5-(aminocarbonyl)methoxybenzonitrile 473924-46-8P, 3-[(3,5-Diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl)oxy]-5-(2-methoxyethoxy)benzonitrile 473924-48-0P, 3-Fluoro-5-[(5-methyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-3-(trifluoromethyl)-1H-pyrazol-4-yl)oxy]benzonitrile 473924-49-1P, 3-Cyano-5-[(3,5-diethyl-1-[2-(2-methoxyethoxy)methoxy]ethyl]-1H-pyrazol-4-yl)oxy]benzamide 473924-50-4P, 5-[(1-Acetyl-3,5-diethyl-1H-pyrazol-4-yl)oxy]isophthalonitrile 473924-51-5P, 5-[(1-Acetyl-3-(1-bromomethyl)-5-ethyl-1H-pyrazol-4-yl)oxy]isophthalonitrile 473924-52-6P, 5-[(5-Ethyl-3-(1-hydroxyethyl)-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl)oxy]isophthalonitrile 473924-53-7P, 3-Cyano-5-[(3,5-diethyl-1-[2-(2-methoxyethoxy)methoxy]ethyl]-1H-pyrazol-4-yl)oxy]-N'-hydroxybenzencarboximide 473924-54-8P, 3-[(3,5-Diethyl-1-[2-(2-methoxyethoxy)methoxy]ethyl]-1H-pyrazol-4-yl)oxy]-5-[5-(5-ethyl-1,2,4-oxadiazol-3-yl)benzonitrile 473924-55-9P (trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzonitrile 473924-56-0P, 3-[(3,5-Diethyl-1-[2-(2-methoxyethoxy)methoxy]ethyl]-1H-pyrazol-4-yl)oxy]-5-[5-(5-ethyl-1,2,4-oxadiazol-3-yl)benzonitrile 473924-57-1P, 3-[(3,5-Diethyl-1-[2-(2-methoxyethoxy)methoxy]ethyl]-1H-pyrazol-4-yl)oxy]-5-[5-isopropyl-1,2,4-oxadiazol-3-yl]benzonitrile  
RL: RCT (Reactant); SPH (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of arylalkyl pyrazole derivs. as reverse transcriptase inhibitors for treating HIV)  
RN 473923-41-0 CAPLUS  
CN 1H-Pyrazole-1-butanolic acid, 4-(3,5-dichlorophenoxy)-3,5-diethyl-β-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 473923-43-2 CAPLUS  
CN 1H-Pyrazole-1-acetic acid, 4-(3,5-dichlorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)


473923-49-8P, 1-Acetyl-4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazole 473923-52-3P, 1-Acetyl-3-(bromomethyl)-4-(3,5-dichlorophenoxy)-5-methyl-1H-pyrazole 473923-61-4P, 4-(3,5-Dichlorophenoxy)-5-ethyl-2-(2-hydroxyethyl)-2,4-dihydro-3H-pyrazol-3-one 473923-63-6P, 2-[2-[(tert-Butyldimethylsilyl)oxy]ethyl]-4-(3,5-dichlorophenoxy)-5-ethyl-2,4-dihydro-3H-pyrazol-3-one 473923-65-8P, 1-[2-[(tert-Butyldimethylsilyl)oxy]ethyl]-4-(3,5-dichlorophenoxy)-3-ethyl-1H-pyrazol-5-yl trifluoromethanesulfonate 473923-70-5P, 3-[(1-Acetyl-3,5-dimethyl-1H-pyrazol-4-yl)oxy]-5-chlorobenzonitrile 473923-73-8P, 3-[(1-Acetyl-3-(bromomethyl)-5-methyl-1H-pyrazol-4-yl)oxy]-5-chlorobenzonitrile 473923-77-2P, N-[[1-[2-[(tert-Butyldimethylsilyl)oxy]ethyl]-4-(3,5-dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl]-N-[(3-pyridinyl)methyl]amine 473923-85-2P, 5-[[1-[2-[(tert-Butyldimethylsilyl)oxy]ethyl]-3-isopropyl-5-methyl-1H-pyrazol-4-yl]oxy]isophthalonitrile 473923-89-6P, 1-[2-[(tert-Butyldimethylsilyl)oxy]ethyl]-4-(3,5-dichlorophenoxy)-3,5-dimethyl-1H-pyrazole 473923-91-0P, 5-(Bromomethyl)-1-[2-[(tert-Butyldimethylsilyl)oxy]ethyl]-4-(3,5-dichlorophenoxy)-3-methyl-1H-pyrazole 473923-92-1P, 3-[[1-[2-[(tert-Butyldimethylsilyl)oxy]ethyl]-3,5-dimethyl-1H-pyrazol-4-yl]oxy]-5-chlorobenzonitrile 473923-93-2P, 3-[(5-Bromomethyl)-1-[2-[(tert-Butyldimethylsilyl)oxy]ethyl]-3-methyl-1H-pyrazol-4-yl)oxy]-5-chlorobenzonitrile 473923-94-3P, 3-[[5-(Aminomethyl)-1-[2-[(tert-Butyldimethylsilyl)oxy]ethyl]-3-methyl-1H-pyrazol-4-yl]oxy]-5-chlorobenzonitrile 473924-12-8P, 3-[[1-[2-[(tert-Butyldimethylsilyl)oxy]ethyl]-3,5-diethyl-1H-pyrazol-4-yl]oxy]-5-fluorobenzonitrile 473924-13-9P, 3-[[3,5-Diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl]oxy]-5-fluorobenzonitrile 473924-14-0P, 3-[[3,5-Diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl]oxy]-5-fluorobenzamide 473924-15-1P, 3-[[3,5-Diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl]oxy]-5-fluorobenzonitrile 473924-17-3P, 5-[[3,5-Diethyl-1-[3-(tetrahydro-2H-pyran-2-yloxy)propyl]-1H-pyrazol-4-yl]oxy]isophthalonitrile 473924-18-4P, 3-[[1-Acetyl-3,5-dimethyl-1H-pyrazol-4-yl]oxy]-5-fluorobenzonitrile 473924-19-5P, 3-[[1-Acetyl-3-(bromomethyl)-5-methyl-1H-pyrazol-4-yl]oxy]-5-fluorobenzonitrile 473924-20-8P, 3-[[3,5-Diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl]oxy]-5-(1,2-dihydro-2-oxo-1-pyridyl)benzonitrile 473924-21-9P, 3-[[3,5-Diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl]oxy]-5-(1,6-dihydro-6-oxo-1,2-diazin-1-yl)benzonitrile 473924-22-0P, 3-[[3,5-Diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl]oxy]-5-(2,5-dihydro-2,3-dimethyl-5-oxo-1H-pyrazol-1-yl)benzonitrile 473924-23-1P, 3-[[3,5-Diethyl-1-acetyl-1H-pyrazol-4-yl]oxy]-5-cyanobenzonitrile 473924-24-2P, 3-[[3,5-Dimethyl-1-acetyl-1H-pyrazol-4-yl]oxy]-5-methylbenzonitrile 473924-25-3P, 3-[[3,5-Dimethyl-1-acetyl-1H-pyrazol-4-yl]oxy]benzonitrile 473924-26-4P, 3-[[3-Bromomethyl-5-methyl-1-acetyl-1H-pyrazol-4-yl]oxy]-5-cyanobenzonitrile 473924-27-5P, 3-[[3-Bromomethyl-5-methyl-1-acetyl-1H-pyrazol-4-yl]oxy]-5-methylbenzonitrile 473924-28-6P, 3-[[3-Bromomethyl-5-methyl-1-acetyl-1H-pyrazol-4-yl]oxy]benzonitrile 473924-34-4P, 4-(3,5-Difluorophenoxy)-3,5-diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazole 473924-36-6P, 4-(3,5-Bis(1H-pyrazol-1-yl)phenoxy)-3,5-diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazole 473924-37-7P, 3,5-Diethyl-4-(3-fluoro-5-(1H-pyrazol-1-yl)phenoxy)-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazole 473924-38-8P, 3-[[3,5-Diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl]oxy]-5-methoxybenzonitrile 473924-42-4P, 3-[[3,5-Diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl]oxy]-5-




RN 473923-49-8 CAPLUS  
CN 1H-Pyrazole, 1-acetyl-4-(3,5-dichlorophenoxy)-3,5-diethyl- (9CI) (CA INDEX NAME)




RN 473923-52-3 CAPLUS  
CN 1H-Pyrazole, 1-acetyl-3-(bromomethyl)-4-(3,5-dichlorophenoxy)-5-methyl- (9CI) (CA INDEX NAME)




RN 473923-61-4 CAPLUS  
CN 3H-Pyrazol-3-one, 4-(3,5-dichlorophenoxy)-5-ethyl-2,4-dihydro-2-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 473923-63-6 CAPLUS  
CN 3H-Pyrazol-3-one, 4-(3,5-dichlorophenoxy)-2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-5-ethyl-2,4-dihydro- (9CI) (CA INDEX NAME)




RN 473923-65-8 CAPLUS  
CN Methanesulfonic acid, trifluoro-, 4-(3,5-dichlorophenoxy)-1-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3-ethyl-1H-pyrazol-5-yl] ester (9CI) (CA INDEX NAME)




RN 473923-70-5 CAPLUS  
CN 1H-Pyrazole, 1-acetyl-4-(3-chloro-5-cyanophenoxy)-3,5-dimethyl- (9CI) (CA INDEX NAME)


RN 473923-85-2 CAPLUS  
CN 1,3-Benzenedicarbonitrile, 5-[[[1-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-5-methyl-3-(1-methylethyl)-1H-pyrazol-4-yl]oxy]]- (9CI) (CA INDEX NAME)




RN 473923-89-6 CAPLUS  
CN 1H-Pyrazole, 4-(3,5-dichlorophenoxy)-1-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)





RN 473923-91-0 CAPLUS  
CN 1H-Pyrazole, 5-(bromomethyl)-4-(3,5-dichlorophenoxy)-1-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 473923-73-8 CAPLUS  
CN 1H-Pyrazole, 1-acetyl-3-(bromomethyl)-4-(3-chloro-5-cyanophenoxy)-5-methyl- (9CI) (CA INDEX NAME)



RN 473923-77-2 CAPLUS  
CN 3-Pyridinamethanamine, N-[[4-(3,5-dichlorophenoxy)-1-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3-methyl-1H-pyrazol-5-yl]methyl]- (9CI) (CA INDEX NAME)




RN 473923-92-1 CAPLUS  
CN Benzonitrile, 3-chloro-5-[[[1-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3,5-dimethyl-1H-pyrazol-4-yl]oxy]]- (9CI) (CA INDEX NAME)




RN 473923-93-2 CAPLUS  
CN Benzonitrile, 3-[[[5-(bromomethyl)-1-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3-methyl-1H-pyrazol-4-yl]oxy]]-5-chloro- (9CI) (CA INDEX NAME)







RN 473923-94-3 CAPLUS  
CN Benzonitrile, 3-[[[5-(aminomethyl)-1-[2-[[[1,1-dimethylethyl]dimethylsilyl]oxy]ethyl]-3-methyl-1H-pyrazol-4-yl]oxy]-5-chloro- (9CI) (CA INDEX NAME)



RN 473924-12-8 CAPLUS  
CN Benzonitrile, 3-[[[1-[2-[[[1,1-dimethylethyl]dimethylsilyl]oxy]ethyl]-3,5-diethyl-1H-pyrazol-4-yl]oxy]-5-fluoro- (9CI) (CA INDEX NAME)




RN 473924-13-9 CAPLUS  
CN Benzonitrile, 3-[[[3,5-diethyl-1-[2-[[[1,1-dimethylethyl]dimethylsilyl]oxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-fluoro- (9CI) (CA INDEX NAME)




RN 473924-14-0 CAPLUS  
CN Benzonitrile, 3-[[[3,5-diethyl-1-[2-[[[1,1-dimethylethyl]dimethylsilyl]oxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-fluoro- (9CI) (CA INDEX NAME)

PAGE 1-A


||  
O

PAGE 2-A


RN 473924-15-1 CAPLUS  
CN Benzonitrile, 3-[[[3,5-diethyl-1-[2-[[[1,1-dimethylethyl]dimethylsilyl]oxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-(1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)




RN 473924-17-3 CAPLUS  
CN 1,3-Benzenedicarbonitrile, 5-[[[3,5-diethyl-1-[2-[[[1,1-dimethylethyl]dimethylsilyl]oxy]ethyl]-1H-pyrazol-4-yl]oxy]propyl]-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 473924-18-4 CAPLUS  
CN 1H-Pyrazole, 1-acetyl-4-(3-cyano-5-fluorophenoxy)-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 473924-19-5 CAPLUS  
CN 1H-Pyrazole, 1-acetyl-3-(bromomethyl)-4-(3-cyano-5-fluorophenoxy)-5-methyl- (9CI) (CA INDEX NAME)




RN 473924-20-8 CAPLUS  
CN Benzonitrile, 3-[[3,5-diethyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-(2-oxo-1(2H)-pyridinyl)- (9CI) (CA INDEX NAME)



RN 473924-23-1 CAPLUS  
CN 1H-Pyrazole, 1-acetyl-3-(bromomethyl)-4-(3,5-dicyanophenoxy)-5-methyl- (9CI) (CA INDEX NAME)




RN 473924-24-2 CAPLUS  
CN 1H-Pyrazole, 1-acetyl-3-(bromomethyl)-4-(3-cyano-5-methylphenoxy)-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 473924-25-3 CAPLUS  
CN 1H-Pyrazole, 1-acetyl-3-(bromomethyl)-4-(3-cyano-5-methylphenoxy)-5-methyl- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 473924-21-9 CAPLUS  
CN Benzonitrile, 3-[[3,5-diethyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-(6-oxo-1(6H)-pyridazinyl)- (9CI) (CA INDEX NAME)




RN 473924-22-0 CAPLUS  
CN Benzonitrile, 3-[[3,5-diethyl-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-1H-pyrazol-4-yl]oxy]-5-(2,5-dihydro-2,3-dimethyl-5-oxo-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)




RN 473924-26-4 CAPLUS  
CN 1H-Pyrazole, 1-acetyl-3-(bromomethyl)-4-(3,5-dicyanophenoxy)-5-methyl- (9CI) (CA INDEX NAME)




RN 473924-27-5 CAPLUS  
CN 1H-Pyrazole, 1-acetyl-3-(bromomethyl)-4-(3-cyano-5-methylphenoxy)-5-methyl- (9CI) (CA INDEX NAME)




RN 473924-28-6 CAPLUS  
CN 1H-Pyrazole, 1-acetyl-3-(bromomethyl)-4-(3-cyano-5-methylphenoxy)-5-methyl- (9CI) (CA INDEX NAME)




RN 473924-34-4 CAPLUS  
CN 1H-Pyrazole, 4-([3,5-difluorophenoxy]-3,5-diethyl-1-[2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl])-(9CI) (CA INDEX NAME)




RN 473924-36-6 CAPLUS  
CN 1H-Pyrazole, 4-([3,5-di-1H-pyrazol-1-ylphenoxy]-3,5-diethyl-1-[2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl])-(9CI) (CA INDEX NAME)




RN 473924-37-7 CAPLUS  
CN 1H-Pyrazole, 3,5-diethyl-4-[3-fluoro-5-(1H-pyrazol-1-yl)phenoxy]-1-[2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl]-(9CI) (CA INDEX NAME)




RN 473924-38-8 CAPLUS  
CN Benzonitrile, 3-([3,5-diethyl-1-[2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl]-1H-pyrazol-4-yl]oxy)-5-methoxy-(9CI) (CA INDEX NAME)




RN 473924-42-4 CAPLUS  
CN Benzonitrile, 3-([3,5-diethyl-1-[2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl]-1H-pyrazol-4-yl]oxy)-5-(methylthio)-(9CI) (CA INDEX NAME)



RN 473924-43-5 CAPLUS  
CN Benzonitrile, 3-([3,5-diethyl-1-[2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl]-1H-pyrazol-4-yl]oxy)-5-(2-(dimethylamino)ethoxy)-(9CI) (CA INDEX NAME)




RN 473924-44-6 CAPLUS  
CN Benzonitrile, 3-([3,5-diethyl-1-[2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl]-1H-pyrazol-4-yl]oxy)-5-(2-(methylamino)ethoxy)-(9CI) (CA INDEX NAME)




RN 473924-45-7 CAPLUS  
CN Acetamide, 2-[3-cyano-5-([3,5-diethyl-1-[2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl]-1H-pyrazol-4-yl]oxy)phenoxy]-(9CI) (CA INDEX NAME)

PAGE 1-A




RN 473924-46-8 CAPLUS  
CN Benzonitrile, 3-[[[3,5-diethyl-1-[(2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]ethyl]-1H-pyrazol-4-yl]oxy]-5-(2-methoxyethoxy)]- (9CI) (CA INDEX NAME)


PAGE 2-A




RN 473924-48-0 CAPLUS  
CN Benzonitrile, 3-[[[3,5-diethyl-1-[(2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]ethyl]-1H-pyrazol-4-yl]oxy]-5-(2-methoxyethoxy)]- (9CI) (CA INDEX NAME)




RN 473924-49-1 CAPLUS  
CN Benzonitrile, 3-[[[3,5-diethyl-1-[(2-[(2-methoxyethoxy)methoxy]ethyl]ethyl]-1H-pyrazol-4-yl]oxy]-5-(2-methoxyethoxy)]- (9CI) (CA INDEX NAME)




RN 473924-50-4 CAPLUS  
CN 1H-Pyrazole, 1-acetyl-4-[(3,5-dicyanophenoxy)]-3,5-diethyl- (9CI) (CA INDEX NAME)




RN 473924-51-5 CAPLUS  
CN 1H-Pyrazole, 1-acetyl-3-[(1-bromoethyl)]-4-[(3,5-dicyanophenoxy)]-5-ethyl- (9CI) (CA INDEX NAME)




RN 473924-52-6 CAPLUS  
CN 1,3-Benzenedicarbonitrile, 5-[[[5-ethyl-3-(1-hydroxyethyl)]-1-[2-




RN 473924-53-7 CAPLUS  
CN Benzenecarboximidamide, 3-cyano-5-[[[3,5-diethyl-1-[(2-[(2-methoxyethoxy)methoxy]ethyl]ethyl]-1H-pyrazol-4-yl]oxy]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 473924-54-8 CAPLUS  
CN Benzonitrile, 3-[[[3,5-diethyl-1-[(2-[(2-methoxyethoxy)methoxy]ethyl]ethyl]-1H-pyrazol-4-yl]oxy]-5-[[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 473924-55-9 CAPLUS  
CN Benzonitrile, 3-([3,5-diethyl-1-[2-((2-methoxyethoxy)methoxy)ethyl]-1H-pyrazol-4-yl]oxy)-5-((5-methyl-1,2,4-oxadiazol-3-yl)-(9CI) (CA INDEX NAME)



RN 473924-56-0 CAPLUS  
CN Benzonitrile, 3-([3,5-diethyl-1-[2-((2-methoxyethoxy)methoxy)ethyl]-1H-pyrazol-4-yl]oxy)-5-((5-ethyl-1,2,4-oxadiazol-3-yl)-(9CI) (CA INDEX NAME)




RN 473924-57-1 CAPLUS  
CN Benzonitrile, 3-([3,5-diethyl-1-[2-((2-methoxyethoxy)methoxy)ethyl]-1H-pyrazol-4-yl]oxy)-5-((1-methylethyl)-1,2,4-oxadiazol-3-yl)-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2001:915238 CAPLUS  
DOCUMENT NUMBER: 136:200148  
TITLE: Screening mixtures: an experiment in pesticide lead generation  
AUTHOR(S): Fisher, Karl J.; Felix, Ray A.; Oliver, Robert M.  
CORPORATE SOURCE: Zeneca Agrochemicals, Richmond, CA, 94804, USA  
SOURCE: ACS Symposium Series (2002), 800 (Synthesis and Chemistry of Agrochemicals VI), 9-15  
CODEN: ACSMCS; ISSN: 0097-6156  
PUBLISHER: American Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
GI




AB Combinatorial libraries of potential herbicidal compds. were prepared by treatment of mixts. of 10 alkyl halides with heterocyclic nucleophiles; the products were then assayed for herbicidal activity. The screening of mixts. was evaluated as a way of improving the rate of new lead generation, one of the greatest challenges facing modern agricultural chemists. Herbicidal activity found in assays of the library compds. was linked in all cases either to a single compound from the mixture or to cumulative effects of multiple active compds. in a mixture. The active compds. were prepared by individual synthesis upon deconvolution. The libraries led to various herbicidal compds., among which was triazolythiobutyramide 1, an active herbicide with a novel mode of action.

IT 401519-80-0P 401519-81-1P 401519-82-2P


401519-83-3P  
RL: AGR (Agricultural use); CFP (Combinatorial preparation); SPN (Synthetic preparation); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)

(preparation of combinatorial libraries of herbicidal compds. by nucleophilic substitution of alkyl halides with heterocyclic nucleophiles and active herbicidal compds. found in the libraries)


RN 401519-80-0 CAPLUS  
CN 1H-Pyrazole-1-acetic acid, 4-(4-chlorophenoxy)-, ethyl ester (9CI) (CA INDEX NAME)




RN 401519-81-1 CAPLUS  
CN 1H-Pyrazole-1-hexanoic acid, 4-(4-chlorophenoxy)-, ethyl ester (9CI) (CA INDEX NAME)




RN 401519-82-2 CAPLUS  
CN 1H-Pyrazole-1-acetic acid, 4-(4-chlorophenoxy)-, ethyl ester (9CI) (CA INDEX NAME)




RN 401519-83-3 CAPLUS  
CN 1H-Pyrazole-1-pentanoic acid, 4-(4-chlorophenoxy)-, ethyl ester (9CI) (CA INDEX NAME)




REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



RN 244270-52-8 CAPLUS  
CN 1H-Pyrazole-1-acetic acid, alpha-(methoxymethylene)-N,3-dimethyl-4-(3-methylphenoxy)- (9CI) (CA INDEX NAME)




RN 244270-53-9 CAPLUS  
CN 1H-Pyrazole-1-acetic acid, alpha-(methoxymethylene)-3-methyl-4-(3-methylphenoxy)-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 1999:631412 CAPLUS  
DOCUMENT NUMBER: 131:243266  
TITLE: Preparation of pyrazoloximinooacetates and related compounds as agrochemical and industrial fungicides.  
INVENTOR(S): Hirohara, Yoji; Sugano, Shigeyoshi; Nakashima, Hideaki; Kimura, Takao; Sakakibara, Takashi  
PATENT ASSIGNER(S): SDS Biotech K.K., Japan  
SOURCE: Eur. Pat. Appl., 70 pp.  
CODEN: EPXOXW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 945437	A1	19990929	EP 1998-105673	19980327
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRIORITY APPL. INFO.: MARPAT 131:243266			EP 1998-105673	19980327
OTHER SOURCE(S):				




AB Title compds. [1] X = CO2R1, CONHR1, CON(R1)2, cyano, 5-6 membered heteroaryl; Y = CH, N; W = alkylene, NR1, Or n = 0, 1; R = alkyl, haloalkyl; A, B, D = H, halo, R1, R10, R15, R150, R1502, (R1)2N, R102C, R10R2, R10N; CH, cyano, NO2, alkenyl, alkynyl, cycloalkyl, (substituted) Ph, PhCH2, PhO, PhCH2O, PhOR2, PhS, PhCH2S, PhSR2, PhCH2ON; CH, naphthyl, heteroaryl; R1 = alkyl, haloalkyl; R2 = alkylene; provided that A, B, D do not all = H and >2 of A, B, D do not = aryl or heteroaryl, were prepared Thus, Me 2-[3-methyl-5-(4-chlorophenyl)pyrazol-1-yl]-2-hydroxyiminoacetate (preparation given) was stirred with Me2SO4 and K2CO3 in DMF to give 82% Me 2-[3-methyl-5-(4-chlorophenyl)pyrazol-1-yl]-2-methoxyiminoacetate. The latter at 500 ppm gave 100% prevention of Pseudoperonospora cubensis on cucumbers.  
IT 244270-51-7P 244270-52-8P 244270-53-9P  
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BSU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(Preparation of pyrazoloximinooacetates and related compds. as agrochem. and industrial fungicides)  
RN 244270-51-7 CAPLUS  
CN 1H-Pyrazole-1-acetic acid, alpha-(methoxymethylene)-3-methyl-4-phenoxy-, methyl ester (9CI) (CA INDEX NAME)


ACCESSION NUMBER: 1998:572284 CAPLUS  
DOCUMENT NUMBER: 129:212968  
TITLE: Preparation of N-aryl-3-aryl-4-substituted-4,5-dihydro-1H-pyrazole-1-carboxamides as insecticides  
INVENTOR(S): Jacobson, Richard Martin  
PATENT ASSIGNER(S): Rohm and Haas Co., USA  
SOURCE: U.S., 49 pp., Cont.-in-part of U.S. Ser. No. 415,117, abandoned.  
CODEN: USXXAH  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5798311	A	19980825	US 1995-468284	19950606
ZA 9105394	A	19920325	ZA 1991-5394	19910711
PRIORITY APPL. INFO.:			US 1990-553220	B2 19900713
			US 1991-713692	B3 19910617
			US 1993-49891	B1 19930419
			US 1995-415117	B2 19950329

OTHER SOURCE(S): MARPAT 129:212968  
GI




AB The N-aryl-3-aryl-4-substituted-4,5-dihydro-1H-pyrazole-1-carboxamides I [R, R1 = H, halo, (halo)alkyl, (halo)alkoxy, nitro, etc.; R2 = H, halo, haloalkyl or haloalkoxy; R3 = halo, haloalkyl or haloalkoxy; V = H, alkyl, alkylcarbonyl, alkoxy, carbonyl or formyl; Y1 = H, alkyl, alkenyl, alkynyl, (halo)phenyl, etc.; Y2 = H, alkyl, alkoxy, carbonyl, cyano, etc.] and I salts are prepared as insecticides.  
IT 141128-27-0P 141128-28-1P  
RL: AGR (Agricultural use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(Preparation as insecticide)  
RN 141128-27-0 CAPLUS  
CN 1H-Pyrazole-1-carboxamide, 3-(4-chlorophenyl)-4,5-dihydro-4-phenoxy-N-(4-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 141128-28-1 CAPLUS  
CN 1H-Pyrazole-1-carboxamide, 4-(4-chlorophenoxy)-3-(4-chlorophenyl)-4,5-dihydro-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:411990 CAPLUS  
DOCUMENT NUMBER: 127:81368  
TITLE: Synthesis of some new oximes, thiocarbamates, pyrazolyloxy, isoxazolyloxy, pyrimidyloxy and pyridyloxy quinolines  
AUTHOR(S): Abdel Hafez, Ali A.  
CORPORATE SOURCE: Chem. Dep., Fac. Sci., Assiut Univ., Assiut, Egypt  
SOURCE: Qatar University Science Journal (1994), 14(Spec. Issue), 108-113  
CODEN: QUSJRV; ISSN: 1023-8948  
PUBLISHER: University of Qatar, Faculty of Science  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
GI




AB The reaction of I or its corresponding chalcones with hydroxylamine in boiling pyridine gave oximes in almost quant. yield. Reaction of the oximes with Ph isothiocyanate gave the corresponding thiocarbamates. A new series of pyrazolyloxy-, isoxazolyloxy-, pyrimidyloxy-, and pyridyloxy-substituted quinolines were obtained. The in vitro antibacterial and antifungal activity were screened for all the compds. prepared; some of the compds. tested showed interesting results.  
IT 191873-96-SP 191873-97-SP 191873-98-OP  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation, bactericidal, and fungicidal activity of (morpholinylsulfonyl)quinolines)  
RN 191873-96-8 CAPLUS  
CN 1H-Pyrazole, 1-acetyl-4,5-dihydro-3-(4-morpholinyl)-4-[[5-(4-morpholinylsulfonyl)-8-quinolinyl]oxy]-5-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 191873-97-9 CAPLUS  
CN 1H-Pyrazole, 1-acetyl-4,5-dihydro-3-(4-methoxyphenyl)-3-(4-morpholinyl)-4-[[5-(4-morpholinylsulfonyl)-8-quinolinyl]oxy]-5-phenyl- (9CI) (CA INDEX NAME)



RN 191873-98-0 CAPLUS  
CN 1H-Pyrazole, 1-acetyl-4,5-dihydro-3-(4-morpholinyl)-4-[[5-(4-morpholinylsulfonyl)-8-quinolinyl]oxy]-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:262919 CAPLUS

DOCUMENT NUMBER: 127:5038

TITLE: Synthesis, reaction, theoretical calculation, NMR study and x-ray crystal structure of 1-substituted and 1-unsubstituted 1H-pyrazol-5(2H)-ones  
 AUTHOR(S): Attanasio, Orazio A.; De Crescenzo, Lucia; Filippone, Pasquale; Foresti, Elisabetta; Galeazzi, Roberto; Ghiviriga, Ion; Katritzky, Alan R.  
 CORPORATE SOURCE: Facolta Scienze, Univ. Urbino, Urbino, 61029, Italy  
 SOURCE: Tetrahedron (1997), 53(15), 5617-5640  
 CODEN: TETRA; ISSN: 0040-4020

PUBLISHER: Elsevier  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English


AB 1-Substituted 4-alkoxy-, 4-alkylthio-, and 4-aryloxy-1H-pyrazol-5(2H)-ones have been prepared by the reaction of conjugated azoalkenes with alcohols, thiols, and phenols. In some cases the intermediate hydrazones were isolated, while in others the products were obtained in one step. 1-Unsubstituted 4-alkoxy-, 4-alkylthio-, and 4-aryloxy-1H-pyrazol-5(2H)-ones were produced by methanolysis of the corresponding 1-substituted derivs. under reflux. Some of these compds. were studied by mol. mechanics calcs., as well as deuterium induced shifts (DIS) on 13C chemical shifts, and tentative conclusion was drawn about their tautomerism and conformations. X-Ray crystal structure detns. of 1-(aminocarbonyl)-3-methyl-4-methoxy-1H-pyrazol-5(2H)-one and 3-methyl-4-methoxy-1H-pyrazol-5(2H)-one demonstrated that both molts. exist in the crystal exclusively in the HN-CO tautomeric form. Some previously reported structural assignments in some pyrazolones and hydroxypyrazoles were corrected

IT 190257-08-0P 190257-09-1P 190257-14-8P 190257-15-9P

RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (synthesis, reaction, theor. calcs., NMR study and x-ray crystal structure of 1H-pyrazol-5(2H)-ones)

RN 190257-08-0 CAPLUS

CN 1H-Pyrazole-1-carboxamide, 2,5-dihydro-3-methyl-4-(4-nitrophenoxy)-5-oxo- (9CI) (CA INDEX NAME)



RN 190257-09-1 CAPLUS

CN 1H-Pyrazole-1-carboxamide, 2,5-dihydro-3-methyl-4-(4-nitrophenoxy)-5-oxo-N-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:35296 CAPLUS

DOCUMENT NUMBER: 124:90281

TITLE: Preparation of 1H-imidazo[1,2-b]pyrazole derivatives

INVENTOR(S): Sato, Tadahisa; Matsuoka, Mitsuyuki

PATENT ASSIGNEE(S): Fuji Photo Film Co Ltd, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.

CODEN: JPKKAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07278455	A2	19951024	JP 1994-68738	19940406
PRIORITY APPLN. INFO.:			JP 1994-68738	19940406
OTHER SOURCE(S):				

G1



AB The title compds. 1 (R1-2 = H, substituent; R3 = H, halo, alkoxy, etc.; R4 = alkyl, aryl; n = 0-2), useful as starting materials for color photog. couplers and dyes, are prepared from 5-amino-1H-pyrazole derivs. Acylating 5-amino-4-chloro-3-methyl-1H-pyrazole with BrCH2COPh in the presence of γ-collidine, reacting the product with PhSSPh in the presence of NaH, and heating at 60° in the presence of HCl gave 1 (R1 = Me; R2, R4 = Ph; R3 = Cl; n = 0).


IT 172887-69-3P

RI: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and cyclization of)

RN 172887-69-3 CAPLUS


CN Ethanone, 2-[5-amino-3-methyl-4-(4-methylphenoxy)-1H-pyrazol-1-yl]-1-phenyl-2-(phenylthio)- (9CI) (CA INDEX NAME)

L6 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 190257-14-8 CAPLUS

CN 1H-Pyrazole-1-carboxamide, 2,5-dihydro-3-methyl-5-oxo-4-phenoxy- (9CI) (CA INDEX NAME)




RN 190257-15-9 CAPLUS

CN 1H-Pyrazole-1-carboxamide, 2,5-dihydro-3-methyl-5-oxo-4-phenoxy-N-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 92 THERE ARE 92 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




IT 172887-64-8P

RI: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and reaction with di-Ph disulfide)

RN 172887-64-8 CAPLUS

CN Ethanone, 2-[5-amino-3-methyl-4-(4-methylphenoxy)-1H-pyrazol-1-yl]-1-phenyl-2-(phenylthio)- (9CI) (CA INDEX NAME)






L6 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1995:677721 CAPLUS  
 DOCUMENT NUMBER: 123:183352  
 TITLE: Silver halide color photographic materials containing timing DIR-couplers  
 INVENTOR(S): Sugino, Motoaki; Asatake, Atsushi; Kaneko, Yutaka  
 PATENT ASSIGNEE(S): Konishiroku Photo Ind, Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 22 pp.  
 CODEN: JKKXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07084348	A2	19950331	JP 1993-229118	19930914
PRIORITY APPLN. INFO.:			JP 1993-229118	19930914
OTHER SOURCE(S):		MARPAT 123:183352		

GI



AB The photog. materials with Ag halide emulsions on supports contain I (R, R1 = H, substituent or ring atom; DI = development inhibitor; TIME = timing group which retards the DI-releasing process; n = 0-2); the development inhibitor is released by reaction with the oxidized developing agent. Image sharpness and storage stability are improved.  
 IT 167381-31-9 167381-35-3 167381-36-4  
 RL: TEM (Technical or engineered material use); USES (Uses) (pyrazolidone photog. development inhibitor-releasing coupler)  
 RN 167381-31-9 CAPLUS  
 CN 1-Pyrazolidineacetic acid, 4-[4-[[[5-amino-4-(2-propenyl)-4H-1,2,4-triazol-3-yl]thio]methyl]-2-[(methylsulfonyl)amino]phenoxy]-3,5-dioxo-2-(2,4,6-trichlorophenyl)-, 1-[(decyloxy)carbonyl]pentyl ester (9CI) (CA INDEX NAME)


PAGE 1-A




L6 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1995:547587 CAPLUS  
 DOCUMENT NUMBER: 123:44276  
 TITLE: Photographic magenta coupler having dioxypyrazolidine nucleus  
 INVENTOR(S): Sugino, Motoaki; Asatake, Atsushi; Kaneko, Yutaka  
 PATENT ASSIGNEE(S): Konishiroku Photo Ind, Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 31 pp.  
 CODEN: JKKXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07036159	A2	19950207	JP 1993-179283	19930720
JP 3208694	B2	20010917		
PRIORITY APPLN. INFO.:			JP 1993-179283	19930720
OTHER SOURCE(S):		MARPAT 123:44276		

GI



AB The coupler has a structure I (R1, R2 = H, substituent; R1 and R2 may form a ring; X = H, leaving group released by the coupling reaction with the developer oxidant). The magenta coupler giving a dye with an excellent stability to light, heat, and humidity.  
 IT 163970-11-4 163970-15-8 163970-18-1  
 163970-19-2  
 RL: TEM (Technical or engineered material use); USES (Uses) (photog. magenta coupler having dioxypyrazolidine nucleus)  
 RN 163970-11-4 CAPLUS  
 CN 1-Pyrazolidineacetic acid, α-(1,1-dimethylethyl)-4-(2-methylphenoxy)-3,5-dioxo-2-phenyl-, decyl ester (9CI) (CA INDEX NAME)




RN 163970-15-8 CAPLUS  
 CN 3,5-Pyrazolidinedione, 4-(4-nitrophenoxy)-1-(1-oxotridecyl)-2-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 1-B

—Me


RN 167381-35-3 CAPLUS  
 CN 1-Pyrazolidinecarboxylic acid, 4-[4-[(3-carboxy-1-oxopropyl)amino]-2-[[[(4,5,6,7-tetrahydro-2-benzothiazolyl)thio]methyl]phenoxy]-3,5-dioxo-2-phenyl-, 1-[2-oxo-2-(tetradecyloxy)ethyl] ester (9CI) (CA INDEX NAME)




RN 167381-36-4 CAPLUS  
 CN 3,5-Pyrazolidinedione, 1-acetyl-4-[2-nitro-4-[[1-(1-phenyl-1H-tetrazol-5-yl)thio]undecyl]phenoxy]-2-phenyl- (9CI) (CA INDEX NAME)




L6 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 163970-18-1 CAPLUS  
 CN 3,5-Pyrazolidinedione, 1-(1-ethyloctyl)-2-(2-methoxyethyl)-4-(2-nitrophenoxy)- (9CI) (CA INDEX NAME)




RN 163970-19-2 CAPLUS  
 CN 1-Pyrazolidineacetic acid, 2-[2-(hexadecylamino)-2-oxoethyl]-4-[4-[(1-methylethoxy)carbonyl]phenoxy]-3,5-dioxo-, methyl ester (9CI) (CA INDEX NAME)




ACCESSION NUMBER: 1992:214493 CAPLUS  
 DOCUMENT NUMBER: 116:214493  
 TITLE: Preparation of N-aryl-3-aryl-4-substituted-4,5-dihydro-1H-pyrazole-1-carboxamides as pesticides  
 INVENTOR(S): Jacobson, Richard Martin  
 PATENT ASSIGNER(S): Rohm and Haas Co., USA  
 SOURCE: Eur. Pat. Appl., 84 pp.  
 CODEN: EPXKDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 466408	A1	19920115	EP 1991-306113	19910704
EP 466408	B1	20000112		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 188690	E	20000115	AT 1991-306113	19910704
ES 2143459	T3	20000516	ES 1991-306113	19910704
CA 2046420	AA	19920114	CA 1991-2046420	19910705
AU 9180313	A1	19920116	AU 1991-80313	19910710
AU 652762	B2	19940908		
ZA 5105394	A	19920325	ZA 1991-5394	19910711
BR 9102980	A	19920211	BR 1991-2980	19910712
HU 58702	A2	19920330	HU 1991-2355	19910712
JP 06080642	A2	19940322	JP 1991-172304	19910712
JP 3321186	B2	20020903		
AU 9480323	A1	19950413	AU 1994-80323	19941208
AU 680315	B2	19970724		
PRIORITY APPLN. INFO.:			US 1990-553220	A 19900713
OTHER SOURCE(S):			US 1991-713692	A 19910617
G1				




AB Title compds. [I; A = (hetero)aryl; Y = isothiocyanato, isocyanato, amino, alkanoyloxy, alkoxy, PhO, alkylthio, phenylthio; Z = H, alkyl; B = (hetero)aryl; U = O, S; V = H, alkyl, alkoxyalkyl, alkylthioalkyl, CHO, alkylcarbonyl, CO2H, PhO, alkoxyalkyl, alkylsulfonyl, PhS, etc.], were prepared. Thus, N-(4-trifluoromethylphenyl)-3-(4-chlorophenyl)-4-carbomethoxy-4-methyl-4,5-dihydro-1H-pyrazole-1-carboxamide was converted successively to the 4-acid, 4-carbonyl chloride, 4-azidocarbonyl derivative, 4-isocyanato derivative and finally to title carboxamide II. II as 600 ppm sprays gave complete control of Epilachna varivestis, Spodoptera eridania.

IT 141128-27-OP 141128-28-1P  
 RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as pesticide)  
 RN 141128-27-0 CAPLUS  
 CN 1H-Pyrazole-1-carboxamide, 3-(4-chlorophenyl)-4,5-dihydro-4-phenoxy-N-(4-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)




RN 141128-28-1 CAPLUS  
 CN 1H-Pyrazole-1-carboxamide, 4-(4-chlorophenoxy)-3-(4-chlorophenyl)-4,5-dihydro-N-(4-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)




ACCESSION NUMBER: 1977:535318 CAPLUS  
 DOCUMENT NUMBER: 87:135318  
 TITLE: 3,4-Disubstituted 2-(β-naphthylthio)ethylpyrazolones  
 INVENTOR(S): Moeller, Eike; Meng, Karl; Seuter, Friedel; Horstmann, Harald  
 PATENT ASSIGNER(S): Bayer A.-G., Fed. Rep. Ger.  
 SOURCE: Ger. Offen., 49 pp.  
 CODEN: GWXKEX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2554701	A1	19770608	DE 1975-2554701	19751205
SE 7613536	A	19770606	SE 1976-13536	19761202
NL 7613451	A	19770607	NL 1976-13451	19761202
BE 849047	A1	19770603	BE 1976-172954	19761203
DK 7605456	A	19770606	DK 1976-5456	19761203
JP 52071467	A2	19770614	JP 1976-144842	19761203
FR 2333505	A1	19770701	FR 1976-36543	19761203
ES 453908	A1	19771116	ES 1976-453908	19761203
PRIORITY APPLN. INFO.:			DE 1975-2554701	A 19751205
G1				




AB Title compds. I (R = Me, R1 = Et, Bu, hexyl, CH2CH2OEt, Ph, CH2CH2OPh, SCF3, OPh, R = Et, R1 = Me, R2 = H, Br) were prepared by condensing 2-(2-naphthylthio)ethylhydrazines with RCOCH(R1)CO2Et. I (R = Me, R1 = hexyl, R2 = H) at 10 mg caused 51% inhibition of thrombus formation in rats.

IT 64076-70-6P 64076-73-9P  
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)  
 RN 64076-70-6 CAPLUS  
 CN 3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-2-[2-(2-naphthalenylthio)ethyl]-4-phenoxy- (9CI) (CA INDEX NAME)




RN 64076-73-9 CAPLUS  
 CN 3H-Pyrazol-3-one, 2-[2-[(5-bromo-2-naphthalenyl)oxy]ethyl]-2,4-dihydro-5-methyl-4-phenoxy- (9CI) (CA INDEX NAME)

L6 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




L6 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1974:403821 CAPLUS  
DOCUMENT NUMBER: 81:3821  
TITLE: Phosgene immonium salts. XIII. Dichloromalonyl cyanines and 3,5-bis(dimethylamino)pyrazoles  
AUTHOR(S): De Voghel, Guy J.; Eggerichs, Terry L.; Janousek, Zdenek; Viehe, Heinz G.  
CORPORATE SOURCE: Lab. Chim. Org., Univ. Louvain, Louvain-la-Neuve, Belg.  
SOURCE: Journal of Organic Chemistry (1974), 39(9), 1233-5  
CODEN: JOCEAH; ISSN: 0022-3263  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
GI For diagram(s), see printed CA Issue.  
AB The chloromalonyl cyanine derivs. (I, R = alkyl, aryl, halo, alkoxy) were synthesized by the reaction of RCH2CONHMe2 with Cl2C:NHMe2 Cl-. The bis-electrophilic system in I is of general applicability to the synthesis of aminated heterocyclic systems. I reacts with hydrazines NH2NHR1 (R1 = Me, Ph, PhSO2 etc.) to give 3,5-bis(dimethylamino)pyrazoles, II.  
IT 50860-18-9P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
RN 50860-18-9 CAPLUS  
CN 1H-Pyrazole-1-carboxylic acid, 3,5-bis(dimethylamino)-4-phenoxy-, ethyl ester (9CI) (CA INDEX NAME)




L6 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1972:488382 CAPLUS  
DOCUMENT NUMBER: 77:88382  
TITLE: 1-Phenyl-2-acetyl-3-amino-2-pyrazolin-5-ones from 1-phenyl 3-azidocarbonyl-2-pyrazolin-5-ones  
AUTHOR(S): Hendess, Raymond W.  
CORPORATE SOURCE: Res. Lab., Eastman Kodak Co., Rochester, NY, USA  
SOURCE: Journal of Organic Chemistry (1972), 37(15), 2400-1  
CODEN: JOCEAH; ISSN: 0022-3263  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 77:88382  
AB The Curtius reaction of 1-phenyl-3-azidocarbonyl-2-pyrazolin-5-one in HOAc leads to 1-phenyl-2-acetyl-3-amino-2-pyrazolin-5-one rather than the expected 1-phenyl-3-acetamido-2-pyrazolin-5-one.  
IT 34804-14-3P 34804-15-4P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
RN 34804-14-3 CAPLUS  
CN 3H-Pyrazol-3-one, 1-acetyl-5-amino-1,2-dihydro-4-(4-methylphenoxy)-2-phenyl- (9CI) (CA INDEX NAME)



RN 34804-15-4 CAPLUS  
CN 3H-Pyrazol-3-one, 1-acetyl-5-amino-1,2-dihydro-4-(4-methylphenoxy)-2-phenyl- (9CI) (CA INDEX NAME)



=> fil reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
92.07	282.99

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-13.14	-13.14

CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 13:51:25 ON 08 APR 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.



STRUCTURE FILE UPDATES: 7 APR 2005 HIGHEST RN 848122-48-5

DICTIONARY FILE UPDATES: 7 APR 2005 HIGHEST RN 848122-48-5

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\*\*\*\*\*



chain nodes :

6 14 15 16 17 18 19

ring nodes :


1 2 3 4 5 7 8 9 10 11 12

chain bonds :

2-14 3-6 5-17 6-7 17-18 18-19

ring bonds :

1-2 1-5 2-3 3-4 4-5 7-8 7-12 8-9 9-10 10-11 11-12



Structure attributes must be viewed using STN Express query preparation.

=> d his

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	43.51	326.50
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-13.14

FILE 'CAPLUS' ENTERED AT 13:52:19 ON 08 APR 2005  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Apr 2005 VOL 142 ISS 16  
 FILE LAST UPDATED: 7 Apr 2005 (20050407/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 16 and 19  
2 L9  
L11 2 L6 AND L9  
=> d ibib 111 1-2



L11 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STM  
 ACCESSION NUMBER: 2004:253142 CAPLUS  
 DOCUMENT NUMBER: 140:287377  
 TITLE: Preparation of pyrazolylloxysophthalonitrile as reverse transcriptase inhibitor in the treatment of AIDS  
 INVENTOR(S): Mowbary, Charles Eric; Price, David Anthony; Selby, Matthew Duncan; Stupples, Paul Anthony  
 PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.  
 SOURCE: PCT Int. Appl., 32 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004024147	A1	20040325	WO 2003-1B3946	20030908
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW				
KV: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZH, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004132793	A1	20040708	US 2003-661947	20030912
PRIORITY APPLN. INFO.:			GB 2002-21477	A 20020916
			GB 2002-23354	A 20021008
			US 2002-433979	P 20021213
REFERENCE COUNT:	3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L11 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STM  
 ACCESSION NUMBER: 2002:832763 CAPLUS  
 DOCUMENT NUMBER: 137:337884  
 TITLE: Preparation of aryloxy pyrazole derivatives as reverse transcriptase inhibitors for treating HIV  
 INVENTOR(S): Jones, Lyn Howard; Mowbary, Charles Eric; Price, David Anthony; Selby, Matthew Duncan; Stupples, Paul Anthony  
 PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.  
 SOURCE: PCT Int. Appl., 306 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085860	A1	20021031	WO 2002-1B1234	20020404
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZH, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
KV: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZH, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2443449	AA	20021031	CA 2002-2443449	20020404
EP 1377556	A1	20040107	EP 2002-708600	20020404
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300497	A	20040216	EE 2003-497	20020404
BR 2002008811	A	20040309	BR 2002-1811	20020404
JF 2004531535	T2	20041014	JF 2002-583387	20020404
US 2003100554	A1	20030529	US 2002-118512	20020405
ZA 2003007095	A	20040910	ZA 2003-7095	20030910
NO 2003004523	A	20031209	NO 2003-4523	20031009
PRIORITY APPLN. INFO.:			GB 2001-8999	A 20010410
			GB 2001-27426	A 20011115
			US 2001-289570P	P 20010508
			US 2002-346727P	P 20020107
			WO 2002-1B1234	W 20020404
OTHER SOURCE(S):	MARPAT 137:337884			
REFERENCE COUNT:	8	THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

3.10

329.60

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-13.14

STN INTERNATIONAL LOGOFF AT 13:53:37 ON 08 APR 2005

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**